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There is an urgent unmet medical need for new treatments for wound and burn infections 
caused by multidrug-resistant Gram-negative “superbugs,” especially the problematic 
Pseudomonas aeruginosa. In this work, the incorporation of colistin, a potent lipopeptide into 
a self-healable hydrogel (via dynamic imine bond formation) following the chemical reaction 
between the amine groups present in glycol chitosan and an aldehyde-modified poly(ethylene 
glycol), is reported. The storage module (G′) of the colistin-loaded hydrogel ranges from 1.3 
to 5.3 kPa by varying the amount of the cross-linker and colistin loading providing different 
options for topical wound healing. The majority of the colistin is released from the hydrogel 
within 24 h and remains active as demonstrated by both antibacterial in vitro disk diffusion 
and time-kill assays. Moreover and pleasingly, the colistin-
loaded hydrogel performs almost equally well as native 
colistin against both the colistin-sensitive and also colistin-
resistant P. aeruginosa strain in the in vivo animal “burn” 
infection model despite exhibiting a slower killing profile in 
vitro. Based on this antibiotic performance along with the bio-
degradability of the product, it is believed the colistin-loaded 
hydrogel to be a potential localized wound-healing formula-
tion to treat burn wounds against microbial infection.
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1. Introduction
In view of the staggering annual costs of wound care 
in Australia ($2.6 billion AUD), the United Kingdom 
(£2.3–3.1 billion), and the United States ($50 billion USD),[1] 
the development of an antibiotic wound care patch for 
the treatment of wound and burn infections caused by 
multidrug-resistant (MDR) “superbugs” will undoubtedly 
result in improved health care on a global scale. Chronic 
wound infections remain a major source of morbidity and 
severe pain in burn patients.[2] The emergence of MDR 
Gram-negative “superbugs” threatens to undermine the 
efficacy of treatments in both the developed and devel-
oping world.[3] P. aeruginosa, for example, is a particularly 
problematic pathogen that is of concern worldwide.[2b,3d,4] 
These problematic bacteria can easily spread within con-
fined environments such as hospitals to immunodeficient 
This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution 
and reproduction in any medium, provided the original work 
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patients,[2b,4b] making the treatment of these patients 
more complex and problematic. Polymyxins remain one 
of the effective treatment options for MDR Gram-negative 
infections.[5] The two clinically used polymyxins, poly-
myxin B and colistin (polymyxin E) specifically bind to 
the lipopolysaccharide (LPS) of the outer membrane of the 
Gram-negative bacteria and bacterial cell death through 
permeabilization of the bacterial outer membrane.[6] Sys-
temic administration of polymyxins remains limited due 
to their high incidence of nephrotoxicity.[7] To date, several 
approaches have been developed to reduce this toxicity.[8] 
It has been demonstrated that the localized applica-
tion of colistin to the infection site can reduce toxicity. 
For example, the clinical treatment of cystic fibrosis lung 
infection patients by local delivery of colistin using nebu-
lized and dry powder aerosolized formulations has proved 
encouraging.[9]
The incorporation of therapeutics in hydrogel formula-
tions has been widely employed to facilitate and manage 
many wound-healing processes, particularly burn 
wounds.[10] Unlike other treatments, the application of 
hydrogels can prevent the loss of the body fluid, keep the 
wound surface hydrated, promote the healing process, 
and also act as a barrier against bacterial infections.[11] 
Properties such as degradability,[12] environmental 
responsiveness,[13] and self-healing[14] can be easily fine-
tuned to support the curing process of specific wound 
types. Among these, chitosan-based hydrogels have 
attracted significant attention due to their unique prop-
erties, such as biocompatibility, biodegradability, and the 
ability to accelerate the healing of wounds in humans.[15]
As colistin is a small lipopeptide antibiotic that is sen-
sitive to many thermal, enzymatic, and chemical con-
ditions, a hydrogel-based delivery platform with facile 
preparation, easy operation, mild gel formation environ-
ment, and high drug loading capacity could be a suit-
able candidate to deliver colistin in a local and effective 
manner to wounds. Recently, Wei and co-workers devel-
oped an injectable chitosan-based hydrogel through 
the utilization of dynamic imine bond chemistry, which 
exhibits high biocompatibility and allows for the con-
trolled storage and release of proteins, and even cells.[16] 
An inexpensive hydrogel can be formed using commer-
cially available glycol chitosan and an easily prepared 
low-toxic aldehyde-modified poly(ethylene glycol) deriv-
ative (DF-PEG),[16b] is a transparent material with self-
healing properties, which can provide better monitoring 
of the wound through direct observation, and improved 
adhesion to the wound. The quick and efficient chemistry 
used allows this hydrogel to be formed either at room 
or body temperatures, which is convenient for topical 
delivery. More importantly, the starting materials of this 
hydrogel, as well as colistin, are highly water soluble, sug-
gesting that colistin could be loaded and distributed into 
the system evenly during the gel formation.
In this present study, we have prepared dynamic glycol 
chitosan/DF-PEG hydrogels loaded with colistin. The 
effects of DF-PEG and colistin concentration on the gel 
material properties were investigated. The release profile 
of colistin was determined both in phosphate-buffered 
saline (PBS) and bacterial growth media by high-perfor-
mance liquid chromatography (HPLC) analysis. Further-
more, the antibacterial activity of the released colistin 
was evaluated in vitro via disk diffusion and time-kill 
experiments. Proof-of-concept in vivo experiments were 
performed using a mouse “burn” infection model.
2. Results and Discussion
2.1. Gel Formation and Characterization
The synthesis of a colistin-loaded hydrogel was achieved 
by integrating colistin into a modification of an estab-
lished hydrogel formulation (Scheme 1).[16b] Instead of the 
original protocol, PBS buffer was used as the solvent in an 
attempt to more closely mimic the wound environment. 
A standard hydrogel was prepared from mixing a 3% w/w 
glycol chitosan solution with either 5% or 10% (w/w) 
DF-PEG solution at a volume ratio of 2.8:1 to achieve the 
targeted strains. Colistin was added either to the glycol chi-
tosan solution or to the DF-PEG solution, and after mixing 
the two solutions a transparent hydrogel was formed 
instantly (typically < 1.6 min).
Macromol. Biosci. 2017,  ,  1600320
Scheme 1. a) Illustration of the synthesis of colistin-containing hydrogel. The chemical structure of b) glycol chitosan, c) DF-PEG, and 
d) colistin A and B.
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Even though colistin itself contains five primary amines 
capable of imine formation, an initial attempt to prepare 
a hydrogel directly from mixing colistin and DF-PEG in 
PBS at the same (20 mg colistin with 500 μL 10% (w/w) 
DF-PEG PBS solution) or a more concentrated condition 
(20 mg colistin with 500 μL 20% (w/w) DF-PEG PBS solu-
tion) was unsuccessful (Figure S1, Supporting Informa-
tion). This may be attributed to the dynamic reversibility 
of the imine bonds under these conditions. In order to act 
as a stable cross-linking point, at least three amines on 
each colistin need to form imine bonds with DF-PEG at 
all times, which is not necessarily easy as the individual 
imine bond is weak and hydrolytically reversible. How-
ever, it is more likely to happen with a multi-functional 
amine-rich material such as glycol chitosan. Also, a more 
stable imine bond can be formed from the glucosamine 
unit on glycol chitosan. Thus, glycol chitosan is necessary 
to this system to obtain a stable hydrogel network.
Since the hydrogel network is mainly dominated by 
glycol chitosan and DF-PEG, the mechanical properties 
of the colistin-loaded hydrogel can be tuned by adjusting 
the amount of the DF-PEG cross-linker. Hydrogels with 
two different amounts of cross-linker were prepared and 
investigated. The hydrogel formation process was not 
affected by the addition of colistin, and more interest-
ingly, the presence of colistin in the formulation accel-
erated the gelation process, which we attribute to the 
increased number of amines in the system (Figure 1). 
The hydrogels prepared using 10% (w/w) DF-PEG solution 
(HG-10) have a larger strain compared to the ones pre-
pared from 5% (w/w) DF-PEG solution (HG-5). The strain 
range of the latter is suitable for application as a topical 
gel, while the higher strain of HG-10 makes it a suitable 
candidate for patch processing.
The self-healing property provided by the dynamic 
imine bond of the original hydrogel has proven to be 
helpful to tissue repair.[16c] To observe whether the self-
healable gel would be affected by the addition of colistin, 
the rheology of the colistin-loaded hydrogels was exam-
ined (Figure S2, Supporting Information). As colistin does 
not interrupt the formation of the main dynamic cross-
linked network of the hydrogels, both hydrogels demon-
strated self-healing properties in the presence of colistin 
while the strain of the hydrogels only reduced slightly 
after three cycles, implying the colistin-loaded hydrogels 
can still provide similar protection on the wound after 
suffering some small damage.
2.2. Colistin Release from the Hydrogel
Since the integration of colistin into the hydrogels was 
successful, the potential for tuning the colistin release 
was investigated. The release rate of colistin was first 
tested in PBS using both HG-5 and HG-10 formulations 
Macromol. Biosci. 2017,  ,  1600320
Figure 1. Storage modulus G′ and loss modulus G″ analyses during gelation process for different hydrogels. (Black: storage modulus; white: 
loss modulus; blue: phase angle; 37 °C; frequency: 1.0 Hz; strain: 5.0%.)
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for comparison. Due to the potency of colistin, the release 
experiment was carried out at relatively low concentra-
tions. A high (5 mg colistin per hydrogel; final colistin 
concentration in solution, 250 mg L−1) and a low dose 
(0.5 mg colistin per hydrogel; final colistin concentration 
in solution, 25 mg L−1) colistin were loaded into both 
hydrogels for the test. In order to confirm colistin is incor-
porated within the hydrogel as opposed to being located 
at the surface, a washing-up step was conducted prior to 
the release study. The recovered wash solutions were sys-
tematically analyzed by HPLC and revealed no detectable 
signals, suggesting near quantitative encapsulation of 
colistin. Interestingly, although adjusting the amount of 
the DF-PEG cross-linker is used to tune the physical proper-
ties of the hydrogels, it has little impact upon the colistin 
release rate under the formulation conditions used herein 
(Figure 2). The colistin concentration difference at each 
sampling time is sufficiently insignificant not to have any 
biological implication for both hydrogels loaded with the 
same amount of colistin. We attribute this observation to 
the dynamic properties of the hydrogel cross-linked net-
work and the weak interactions between colistin and the 
hydrogel scaffold. The low colistin loading may also be one 
of the reasons for the little difference of the release rate 
between the HG-5 and HG-10 formulations.
Similarly, the release of colistin was tested in cation-
adjusted Mueller–Hinton (CAMHB) bacterial growth 
media to evaluate the effect of a complex biological 
media on the colistin release rate. Even though the 
CAMHB contains amino acids, proteins, and various ions, 
which is very different to PBS, the release profiles of both 
colistin-loaded hydrogels were found to be very similar 
(Figure 2). Again, under these conditions the amount 
of the cross-linker in the hydrogel did not have a great 
influence on the release of colistin due to similar reasons 
described above. All of these results suggest that the anti-
biotic activity between these two colistin-loaded hydro-
gels should be similar.
2.3. In Vitro Bio-Activity Evaluation of 
Colistin-Loaded Hydrogels
The activity of the colistin-loaded gels 
was investigated in vitro against two P. 
aeruginosa strains, a colistin-sensitive 
strain (ATCC 27853, minimum inhibi-
tory concentration (MIC) = 1 mg L−1) and 
a colistin-resistant strain cystic fibrosis 
isolate (19147 n/m, MIC > 128 mg L−1).
First, a disk diffusion assay was used to 
evaluate the release of colistin from the 
hydrogel through the interface (Figure 3). 
Briefly, the colistin-loaded hydrogels were 
placed on an agar plate surface that was 
swabbed with a bacterial isolate solution 
and the plate was then incubated for 24 h. A clear bacteria-
free zone, also known as zone of inhibition (ZoI), would be 
found from the samples that have antibiotic activity and the 
larger size of ZoI indicates a higher potency of the sample.
Although the hydrogel per se did not show any inhibi-
tion against the bacteria, clear ZoIs were found from the 
colistin-sensitive P. aeruginosa strain when colistin-loaded 
hydrogels were applied (Figure 3a, left lane), suggesting 
that colistin is effectively released from the colistin-loaded 
hydrogels to the bacterial interface and more importantly, 
that the released colistin remains active.
ZoIs of similar size were found between both colistin-
loaded hydrogels (HG-5 and HG-10) against the P. aerugi-
nosa strain, in accordance with the similar colistin release 
after 24 h from the release profile (Figure 2), proposing 
the two colistin-loaded hydrogels have similar antibac-
terial properties despite the difference of their physical 
properties. More importantly, the colistin-loaded hydro-
gels showed similar activity to commercial colistin disks 
containing the same amount of colistin (10 μg), indi-
cating the released colistin has almost the same activity 
against the P. aeruginosa bacteria as the native one and 
the hydrogel does not severely hinder or alter the activity 
of the colistin. Similar results were also found from the 
colistin-resistant P. aeruginosa strain (Figure 3a, right 
lane). Owing to the high loading capacity of the hydrogel, 
it was possible to increase the loading of colistin into 
the hydrogel of the same size. With the higher loading 
of the colistin (100 μg colistin per hydrogel), the hydro-
gels showed the expected enhanced antibiotic perfor-
mance against the bacteria when compared to the com-
mercial disks. In order to obtain a better understanding 
of the killing kinetics of the colistin-loaded hydrogels, 
time-dependent bacterial inhibition experiments (time-
kill experiments) were conducted (Figure 4). Briefly, the 
colistin-loaded hydrogels were introduced into the broth 
containing bacteria at the logarithmic phase of growth 
and the broth samples were taken periodically for viable 
Macromol. Biosci. 2017,  ,  1600320
Figure 2. The release study in PBS and cation-adjusted Mueller–Hinton broth. The data 
of HG-5 are described in dashed lines and HG-10 in solid lines. (The release traces of the 
blank hydrogels overlap with the x-axis.)
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counts. As the growth of the colistin-sensitive P. aerugi-
nosa strain can be easily inhibited at a very low colistin 
concentration, only the colistin-resistant strain was inves-
tigated in these time-kill studies. Although the MIC of the 
colistin-resistant strain is greater than 128 mg L−1, colistin 
solution at a final concentration of 25 mg L−1 inhibited the 
growth of the bacteria from 0.5 to 6 h. On the contrary, 
the lower colistin dose (0.5 mg colistin per hydrogel; final 
colistin concentration in solution, 25 mg L−1) hydrogels, 
showed a lower level of activity. This is mainly due to the 
difference diffusion profiles obtained from the two solu-
tions and the hydrogel–solution interface. The slower 
colistin release provided by colistin-loaded hydrogel 
in the first few hours results in a lower local concentra-
tion of released colistin, compared with the colistin solu-
tion, thus inhibition of the growth of bacteria at that 
dose is not observed. To increase the initial local colistin 
concentration, a higher concentration of colistin was 
loaded into the hydrogels (5 mg colistin per hydrogel; 
final colistin concentration in solution, 250 mg L−1). At this 
loading, colistin-loaded hydrogels showed a much better 
performance against the resistant P. aeruginosa strain. 
Fitted with the previous colistin release curve (Figure 2), 
the difference of the killing profiles between HG-5 and 
HG-10 was again very subtle, indicating similar concen-
trations of colistin with similar antibiotic ability were 
released from both colistin-loaded hydrogels. Although a 
slightly slower killing profile was still observed compared 
to solution containing the same amount of colistin, due to 
the reduced initial local concentration provided from the 
hydrogels, the survival bacteria number was significantly 
decreased (Figure 4).
2.4. In Vivo Animal “Burn” Infection 
Model Test of Colistin Hydrogels
An animal “burn” infection model 
was also developed to evaluate the 
gel performance in vivo (see the Sup-
porting Information for the details). 
Animal experiments were approved by 
the institutional animal ethics com-
mittee and animals were maintained 
in accordance with the criteria of the 
Australian code of practice for the care 
and use of animals for scientific pur-
poses. Both the colistin-sensitive strain 
and the resistant strain were tested. Due 
to the biodegradability of the hydrogels, 
Macromol. Biosci. 2017,  ,  1600320
Figure 3. a) Disk diffusion assay for the colistin-loaded hydrogels against the colistin-sensitive (left) and colistin-resistant (right) P. aeruginosa 
strains. b) Zone of inhibition (ZoI) results of the colistin-loaded hydrogels. Blank: commercial blank disc; Col: commercial colistin disk (contains 
10 μg colistin); HG-10/5: blank hydrogels; HG-10/5-L: hydrogels loaded with 10 μg colistin; HG-10/5-H: hydrogels loaded with 100 μg colistin.
Figure 4. Time-kill test of the colistin-loaded hydrogels. Black lines: blank control and 
blank hydrogels; red lines: samples loaded with 0.5 mg colistin (final concentration: 
25 mg L−1); blue lines: samples loaded 5 mg colistin (final concentration: 250 mg L−1). The 
detection limit is shown in dashed line.
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a visible weight loss was found in both colistin-loaded 
hydrogels during the test (Figure S4, Supporting Informa-
tion). Since the HG-5 hydrogel required a longer gelation 
time and it exhibited a faster degradation rate in vivo, only 
the HG-10 formulation was examined in vivo. 100 μL 109 
CFU mL−1 of bacteria at the early logarithmic growth phase 
was inoculated onto the wound (1 cm2) of each mouse, 
2 h in advance of the test. Then patches made from 
colistin solution, colistin-loaded hydrogel, or blank hydro-
gels were applied onto the wound at time = 0 h. Colistin 
(0.3 mg) was loaded into the hydrogel to kill the colistin-
sensitive strain. Surprisingly, in spite of the slower colistin 
release in vitro, the colistin-loaded hydrogel performed as 
comparably to colistin solution in vivo (Figure 5). In the 
case of the resistant strain, the colistin concentration was 
not sufficient to kill the bacteria independently if it was 
applied in the hydrogel or as a solution (Figure S5, Sup-
porting Information). Therefore, a higher dose (1.5 mg 
colistin) was used instead to kill the resistant strain. 
Although the killing profile is slower due to the nature 
of the resistant strain, the colistin-loaded hydrogel again 
showed a similar activity as the colistin solution, leading 
to ≈2 logarithm reduction of the bacteria population (i.e., 
≈99% bacteria population was killed) (Figure 5). This 
implies that the hydrogel formulation did not inhibit the 
activity of the colistin in vivo even though it has a slower 
release rate than that observed in the time-kill study. This 
may partially be attributed to the similar diffusion profile 
obtained from the wound interface but also through the 
enhanced degradation of the hydrogel in the biologically 
complex nature of the local wound environment. More-
over, since the colistin-loaded hydrogels were applied 
directly onto the burn wound, it appears that the local 
concentration on the wound was high enough to kill the 
bacteria while all the tested mice survived suggesting the 
overall systemic concentration and toxicity remained low.
3. Conclusion
In summary, we have successfully prepared self-healing 
colistin-loaded hydrogels by incorporating colistin into an 
inexpensive, biocompatible, and biodegradable chitosan 
hydrogel. The hydrogel structure was not affected by 
the addition of the colistin lipopeptide and the colistin-
loaded hydrogels inherited all of the properties from the 
original hydrogel without disrupting their desired phys-
ical properties. Interestingly, the hydrogel formation pro-
cess could be accelerated in the presence of the colistin. 
Colistin is released from the hydrogel at a similar rate at 
body temperature in different buffers. The disk diffusion 
assay showed that the released colistin remained active 
and had comparable antibacterial activity as the colistin 
solution. Although the colistin-loaded hydrogels showed 
a slower killing profile in vitro compared with the colistin 
solution, it performed as well as the colistin solution in 
vivo thanks to the biodegradable and dynamic nature of 
this glycol chitosan hydrogel. Furthermore, a wide range 
of colistin loading was easily achievable, thus allowing 
the tuning of the release of colistin for different applica-
tions. Indeed, we demonstrated that even the colistin-
resistant P. aeruginosa strains can easily be killed in vivo 
in a mouse burn infection model. Finally, we have dem-
onstrated this hydrogel can achieve the localized release 
of active colistin without causing any toxicity to the mice. 
This colistin-loaded hydrogel holds significant potential 
for the treatment of chronic wound infections caused by 
problematic Gram-negative “superbugs.”
Supporting Information
Supporting Information is available from the Wiley Online 
Library or from the author.
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Figure 5. The “burn” infection model test of the colistin-loaded hydrogel against a) colistin-sensitive and b) colistin-resistant strain. Black 
line: blank infection control; red line: blank HG-10 hydrogel; blue line: HG-10 with colistin (0.3 mg/wound for sensitive strain and 1.5 mg/
wound for resistant one); pink line: colistin solution (0.3 mg/wound for sensitive strain and 1.5 mg/wound for resistant one). The detection 
limit is shown in dashed line.
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